A new study shows that a two-dose COVID-19 vaccine developed by Pfizer and BioNTech is 90% effective at preventing someone from being hospitalized with the virus for up to six months after receiving a second dose.
Researchers from Pfizer and the US-based health care consortium Kaiser Permanente looked at the records of nearly 3.4 million people who were members of Kaiser’s Southern California health insurer and provider program between December 2020 and August this year.
The study, published Monday in The Lancet medical journal, also showed that the vaccine was 93% effective against the highly contagious delta variant for at least six months after the second shot.
But the researchers also found that the vaccine’s effectiveness against the infection dropped from 88% to 47% after six months.
The new study was published on the same day that the European Union’s drug regulator approved the use of booster shots of the Pfizer-BioNTech COVID-19 vaccine for people 18 years and older, but it took individual Left to different countries whether to recommend or not. Shots for wide use.
The European Medicines Agency said in a statement on Monday that a booster dose of the Pfizer vaccine “may be considered for at least 6 months after the second dose for people 18 years of age and older.”
The agency said people with severely weakened immune systems should be given a third dose of Pfizer or Moderna Vaccine at least 28 days after getting their second shot.
The guidance comes as some EU member states have begun administering booster shots, while others are still debating how widely to use boosters in their populations.
Meanwhile, the New York Times newspaper said on Monday that Johnson & Johnson will ask the US Food and Drug Administration to approve a booster shot of its single-dose COVID-19 vaccine.
The US drugmaker announced last month that clinical trials show its second shot of the vaccine increased its effectiveness against the virus to 94% about two months after the first dose, which provided about 70% effectiveness.
Johnson & Johnson said the company is submitting the results of its study to the FDA, the US Centers for Disease Control and Prevention, the European Medicines Agency and other health authorities for possible use of the vaccine as a booster, eight months or so after the primary Is. Single dose vaccination.
Johnson & Johnson’s request comes less than two weeks after the FDA approved a third shot of the Pfizer-BioNTech two-dose COVID-19 vaccine for Americans 65 and older and adults at high risk of serious illness. authorized. The FDA is currently considering whether to approve a third shot of the two-dose Moderna vaccine.
Some information for this report has been received from the Associated Press and Reuters.